<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Open Science Publishers LLP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>TOPOCHEMICAL STUDIES ON 4(3H)-QUINAZOLINONES AS DIHYDROFOLATE REDUCTASE (DHFR) INHIBITORS: AN APPROACH TO PREDICT THE ANTITUMOR ACTIVITY&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>M.</surname><given-names>Ramesh</given-names></name></contrib><contrib contrib-type="author"><name><surname>C.</surname><given-names>Balakumar</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>26</day><month>07</month><year>2013</year></pub-date><volume>03</volume><issue>11</issue><fpage>17</fpage><lpage>27</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Background of study: Inhibition of DHFR is one of the potential targets for anticancer therapy. In this study, topochemical descriptor based calculations were carried out on substituted 4(3H)-quinazolinones to predict DHFR inhibition. A data set of 50 molecules of substituted 4(3H)-quinazolinones as potential DHFR inhibitors and its topological descriptors like Wiener__ampersandsignrsquo;s index, Balaban__ampersandsignrsquo;s index and Molecular topological index were investigated. Objective: The topological data was systematically analyzed and suitable descriptor based topochemical models were developed after the identification of the active ranges. Research methodology: Subsequently, the DHFR inhibition activity was predicted for all the data set of molecules using topochemical models. Then, the predicted activity was compared with the experimentally reported DHFR inhibitor activity. Results: The overall prediction of DHFR inhibition was found to be higher accuracy of 80% for the models based on Wiener__ampersandsignrsquo;s index as well as Molecular topological index and 74% for Balaban__ampersandsignrsquo;s index. Conclusions: The prediction of DHFR inhibition using topochemical descriptors can be useful to design newer analogues of quinazolines as potential DHFR inhibitors.&#13;
</p></abstract><kwd-group><kwd>Dihydrofolate reductase</kwd><kwd> Wiener’s index</kwd><kwd> Balaban’s index</kwd><kwd> Molecular topological index  and 4(3H)-quinazolinone</kwd><kwd> Antitumor action.</kwd></kwd-group></article-meta></front></article>
